登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C27H29NO11 · HCl
化学文摘社编号:
分子量:
579.98
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
EC Number:
246-818-3
Beilstein/REAXYS Number:
4229251
MDL number:
InChI
1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,17-,22+,27-;/m0./s1
InChI key
MWWSFMDVAYGXBV-RUELKSSGSA-N
SMILES string
Cl[H].COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO
grade
pharmaceutical primary standard
API family
doxorubicin
manufacturer/tradename
EDQM
mp
216 °C (dec.) (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
Gene Information
human ... TOP2A(7153)
正在寻找类似产品? 访问 产品对比指南
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets, has been developed and issued under the Authority of the Issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
Produced by certain strains of Streptomyces coeruleorubidus or Streptomyces peucetius or obtained by any other means.
For further information and support please go to the website of the issuing Pharmacopoeia.
Produced by certain strains of Streptomyces coeruleorubidus or Streptomyces peucetius or obtained by any other means.
Application
This European Pharmacopoeia reference standard is intended for use only as specifically prescribed in the European Pharmacopoeia. Their suitability for any other use is not guaranteed and is the sole responsibility of the user. This standard is not intended for human or animal use.
Established for the preparation of the below-given solutions as per European Pharmacopoeia:
Established for the preparation of the below-given solutions as per European Pharmacopoeia:
- Reference solutions (b) and (c) in the testing of related substances in daunorubicin hydrochloride using liquid chromatography (General text 2.2.29), according to the monograph 0662
- Reference solutions (a) and (c) to test related substances in doxorubicin hydrochloride using liquid chromatography (General text 2.2.29), according to the monograph 0714
- Reference solutions (b) and (c) in the testing of related substances in epirubicin hydrochloride using liquid chromatography (General text 2.2.29), according to the monograph 1590
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Carc. 1B - Muta. 1B - Repr. 1B
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
涉药品监管产品
此项目有
Daunorubicin hydrochloride
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 2343-2344 (2008)
Doxorubicin hydrochloride
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 2471-2472 (2008)
Maide Gökçe Bekaroğlu et al.
Materials science & engineering. C, Materials for biological applications, 103, 109838-109838 (2019-07-28)
The objective of the study was to obtain multifunctional core shell nanostructures of superparamagnetic iron oxide nanoparticles (Fe3O4) coated with various ionic biopolymers that can optimize toxicity to healthy cells, colloidal instabilities and drug loading capacities. These nanostructures can also
Epirubicin hydrochloride
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 4974-4975 (2021)
C Main et al.
Health technology assessment (Winchester, England), 10(9), 1-132 (2006-03-21)
To examine the clinical effectiveness and cost-effectiveness of intravenous formulations of topotecan monotherapy, pegylated liposomal doxorubicin hydorocholoride (PLDH) monotherapy and paclitaxel used alone or in combination with a platinum-based compound for the second-line or subsequent treatment of advanced ovarian cancer.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持